Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Blood (2023) 141 (15): 1846–1857.

https://doi.org/10.1182/blood.2022018108

Published: 2023

Includes: Supplemental data

Journal Articles

Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606)

Blood (2015) 126 (23): 322.

https://doi.org/10.1182/blood.V126.23.322.322

Published: 2015

Journal Articles

Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911)

Eugen Tausch, MD, Christina Galler, Richard Schlenk, MD, Peter Hillmen, MBChB, PhD, Fritz Offner, MD, Ann Janssens, MD, K Govindbabu, MD, Jiri Mayer, MD, Sebastian Grosicki, MD, Panagiotis Panagiotidis, Daniel Mertens, PhD, Astrid McKeown, PhD, Ira Gupta, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1992.

https://doi.org/10.1182/blood.V124.21.1992.1992

Published: 2014

Journal Articles

NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia

Krzysztof Giannopoulos, MD PhD, Malgorzata Zajac, Anna Dolnik, Matthias Schunn, Stephany Correa, Eliza Glodkowska-Mrowka, MD, Reddy Chakkarappan Sundaram, Olga Jankowska-Lecka, Richard Schlenk, MD, Konstanze Dohner, MD, Lars Bullinger, MD

Blood (2014) 124 (21): 2338.

https://doi.org/10.1182/blood.V124.21.2338.2338

Published: 2014

Journal Articles

Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications

Blood (2014) 123 (6): 914–920.

https://doi.org/10.1182/blood-2013-07-518746

Published: 2014

Includes: Supplemental data

Journal Articles

Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).

Jan Krönke, Richard Schlenk, Kai-Ole Jensen, Karina Eiwen, Marianne Habdank, Daniela Späth, Jürgen Krauter, Arnold Ganser, Prof./M.D., Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Hartmut Döhner, Konstanze Döhner

Blood (2009) 114 (22): 1586.

https://doi.org/10.1182/blood.V114.22.1586.1586

Published: 2009

Journal Articles

High EVI1 Expression Predicts Outcome in Younger Adult (15 to 60 years) Patients with Acute Myeloid Leukemia and Is Associated with Distinctive Cytogenetic Subgroups.

Gröschel Stefan, Sanne Lugthart, Richard Schlenk, Peter Valk, Karina Eiwen, Chantal Goudswaard, Willem JL Van Putten, Sabine Kayser, Leo Verdonck, Michael Lübbert, Gert Ossenkoppele, Ulrich Germing, Ingo Schmidt-Wolf, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Bob Löwenberg, Konstanze Döhner, Ruud Delwel

Blood (2009) 114 (22): 582.

https://doi.org/10.1182/blood.V114.22.582.582

Published: 2009

Journal Articles

Genome-Wide Analysis of Alternative Splicing Points to Novel Leukemia Relevant Genes in Acute Myeloid Leukemia.

Anna Dolnik, Andreas Gerhardinger, Ursula Botzenhardt, Sabrina Heinrich, Richard Schlenk, Hartmut Dohner, Konstanze Doehner, Karlheinz Holzmann, Lars Bullinger

Blood (2009) 114 (22): 2391.

https://doi.org/10.1182/blood.V114.22.2391.2391

Published: 2009

Journal Articles

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG)

Jan Krönke, Richard Schlenk, Kai-Ole Jensen, Karina Eiwen, Marianne Habdank, Daniela Späth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Konstanze Döhner

Blood (2008) 112 (11): 699.

https://doi.org/10.1182/blood.V112.11.699.699

Published: 2008

Journal Articles

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. Müller-Tidow, MD, Gesine Bug, MD, Richard Schlenk, MD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, Juergen Krauter, MD, David Nachbaur, MD, Peter Valent, MD, Tillmann Taube, MD, Gerd Munzert, MD, Kang-Hun Lee, MD, Hartmut Dohner, MD

Blood (2008) 112 (11): 2973.

https://doi.org/10.1182/blood.V112.11.2973.2973

Published: 2008

Journal Articles

Interim Results of a Phase I/II Clinical Trial of Belinostat in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy.

Richard Schlenk, Kristina Sohlbach, Marie-Luise Hütter, Patrice Ceballos, Nathalie Fegueux, MD, Emmanuel Raffoux, Herve Dombret, MD, Mike Dennis, Jo Tomlins, Jette Tjørnelund, Andreas Neubauer

Blood (2008) 112 (11): 1953.

https://doi.org/10.1182/blood.V112.11.1953.1953

Published: 2008

Journal Articles

Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML.

Lars Bullinger, Thomas Hielscher, Ursula Botzenhardt, Sabrina Heinrich, Richard Schlenk, Jonathan R. Pollack, Konstanze Dohner, Axel Benner, Hartmut Dohner

Blood (2008) 112 (11): 1487.

https://doi.org/10.1182/blood.V112.11.1487.1487

Published: 2008

Journal Articles

Role of Etoposide in Combination with All- Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation

Marie-Luise Hütter, Konstanze Döhner, Ingo G.H. Schmidt-Wolf, Francisco Del Valle, Björn Heydrich, Wolfgang Heit, Walter Fiedler, Michael Pfreundschuh, MD, PhD, Gudrun Russ, Martin Bentz, Aruna Raghavachar, Detlef Haase, MD, PhD, Wolfram Brugger, MD, Katharina Götze, Silja Groner, Hartmut Döhner, Richard Schlenk

Blood (2008) 112 (11): 559.

https://doi.org/10.1182/blood.V112.11.559.559

Published: 2008

Journal Articles

KIT Mutations Define Characteristic Gene Expression Signatures in Core Binding Factor Leukemias.

Sonja C. Schmid-Fetzer, Juan Du, Stephan Kurz, Claudia Scholl, Sandrine Sander, Andrea Corbacioglu, Annika C. Russ, Stefan Frohling, Richard Schlenk, John R. Pollack, Konstanze Dohner, Hartmut Dohner, Lars Bullinger

Blood (2007) 110 (11): 3163.

https://doi.org/10.1182/blood.V110.11.3163.3163

Published: 2007

Journal Articles

Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup.

Jürgen Krauter, MD, Katharina Wagner, M.D., Irina Schäfer, Rolf Marschalek, Ph.D., Claus Meyer, M.D., Gerhard Heil, M.D., Markus Andreas Schaich, M.D., Gerhard Ehninger, M.D., Dietger W. Niederwieser, M.D., Rainer Krahl, M.D., Thomas Buchner, M.D., Cristina Sauerland, Brigitte Schlegelberger, M.D., Konstanze Dohner, M.D., Hartmut Dohner, M.D., Richard Schlenk, M.D., Arnold Ganser, M.D.

Blood (2007) 110 (11): 759.

https://doi.org/10.1182/blood.V110.11.759.759

Published: 2007

Journal Articles

Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup.

Jürgen Krauter, MD, Katharina Wagner, M.D., Irina Schäfer, Rolf Marschalek, Ph.D., Claus Meyer, M.D., Gerhard Heil, M.D., Markus Andreas Schaich, M.D., Gerhard Ehninger, M.D., Dietger W. Niederwieser, M.D., Rainer Krahl, M.D., Konstanze Dohner, M.D., Hartmut Dohner, M.D., Richard Schlenk, M.D., Arnold Ganser, M.D.

Blood (2006) 108 (11): 16.

https://doi.org/10.1182/blood.V108.11.16.16

Published: 2006

Journal Articles

Autologous graft-versus-host disease–like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia

Thorsten Zenz, Matthias Ritgen, Peter Dreger, Alexander Kröber, Thomas F. Barth, Richard Schlenk, Sebastian Böttcher, Michael J. Hallek, Michael Kneba, Donald Bunjes, Hartmut Döhner, Stephan Stilgenbauer

Blood (2006) 108 (6): 2127–2130.

https://doi.org/10.1182/blood-2006-04-007898

Published: 2006

Includes: Supplemental data

Journal Articles

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Michael Lübbert, Björn Rüter, Mathias Schmid, Sabine Knipp, Ulrich Germing, Christiane Dobbelstein, Hartmut Eimermacher, Barbara Deschler, Rainer Claus, Richard Schlenk, Arnold Ganser, Hartmut Döhner, Claudia Schmoor, Hartmut Henß

Blood (2005) 106 (11): 1852.

https://doi.org/10.1182/blood.V106.11.1852.1852

Published: 2005

Journal Articles

Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the AML-SG and SHG-Dresden Study Groups.

Jürgen Krauter, MD, Irina Schäfer, Anke Kohlenberg, MD, Katharina Wagner, MD, Gerhard Heil, MD, Markus Schaich, MD, Gerhard Ehninger, MD, Konstanze Döhner, MD, Hartmut Döhner, MD, Richard Schlenk, MD, Arnold Ganser, MD

Blood (2005) 106 (11): 2360.

https://doi.org/10.1182/blood.V106.11.2360.2360

Published: 2005

Journal Articles

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR

Matthias Ritgen, Stephan Stilgenbauer, Nils von Neuhoff, Andreas Humpe, Monika Brüggemann, Christiane Pott, Thorsten Raff, Alexander Kröber, Donald Bunjes, Richard Schlenk, Norbert Schmitz, Hartmut Döhner, Michael Kneba, Peter Dreger

Blood (2004) 104 (8): 2600–2602.

https://doi.org/10.1182/blood-2003-12-4321

Published: 2004

NARROW

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606)

Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911)

NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia

Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications

Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).

High EVI1 Expression Predicts Outcome in Younger Adult (15 to 60 years) Patients with Acute Myeloid Leukemia and Is Associated with Distinctive Cytogenetic Subgroups.

Genome-Wide Analysis of Alternative Splicing Points to Novel Leukemia Relevant Genes in Acute Myeloid Leukemia.

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG)

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

Interim Results of a Phase I/II Clinical Trial of Belinostat in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy.

Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML.

Role of Etoposide in Combination with All- Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation

KIT Mutations Define Characteristic Gene Expression Signatures in Core Binding Factor Leukemias.

Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup.

Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup.

Autologous graft-versus-host disease–like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the AML-SG and SHG-Dresden Study Groups.

Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only